Trials / Completed
CompletedNCT06632561
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- Ashraf Wasfy Beshay Aziz · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a short to mid-term randomized single-blind placebo controlled study that aimed to detect the effects of empagliflozin (a sodium-glucose cotransporter-2 inhibitor) compared to placebo on LV end-diastolic and end-systolic volumes, LV ejection fraction, N-terminal pro-B-type natriuretic peptide (NT-proBNP), functional capacity and quality of life (QoL) among non-diabetic patients with HFrEF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin 10 mg | Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months |
| DRUG | Placebo | Sugar pills one tablet daily for 6 months |
Timeline
- Start date
- 2021-07-26
- Primary completion
- 2022-03-09
- Completion
- 2022-03-14
- First posted
- 2024-10-09
- Last updated
- 2024-10-09
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06632561. Inclusion in this directory is not an endorsement.